Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics Announces H1 Results for 2018

  • Read more about Bone Therapeutics Announces H1 Results for 2018

Bone Therapeutics: Information on the total number of voting rights and shares

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

  • Read more about Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society

  • Read more about Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society

Bone Therapeutics: Information on the total number of voting rights and shares (2018-09)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (2018-09)

Single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

  • Read more about Single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

Bone Therapeutics: Information on the total number of voting rights and shares (October 2018)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (October 2018)

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

  • Read more about Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

  • Read more about Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

Bone Therapeutics Business Update for Third Quarter 2018

  • Read more about Bone Therapeutics Business Update for Third Quarter 2018

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions